Company Overview
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +193.11% |
| 6 Months: | +69.21% |
| 3 Months: | +23.13% |
| 1 Month: | +17.23% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)52.38 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EWTX Edgewise Therapeutics, Inc. R2K | 40.83 | -24.60 | $4.39B | 0.00% | -36.44% | -38.14% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -3.25M | -3.96M | -3.64M | -6.86M | -10.46M | -13.08M | -14.83M | -16.49M | -18.26M | -25.70M | -25.34M | -29.45M | -34.75M | -38.11M | -40.43M | -45.96M | -42.61M | -46.86M | -54.12M |
| Net Income | -3.19M | -3.95M | -3.64M | -6.82M | -10.35M | -12.95M | -14.66M | -16.07M | -17.50M | -22.84M | -21.47M | -25.71M | -28.52M | -31.50M | -34.13M | -40.80M | -36.12M | -40.67M | -49.01M |
| Diluted EPS | - | - | - | -4.37 | -0.21 | -0.26 | -0.30 | -0.32 | -0.34 | -0.36 | -0.34 | -0.41 | -0.33 | -0.34 | -0.36 | -0.43 | -0.34 | -0.39 | -0.46 |
| R&D Expense | 2.97M | 3.64M | 3.24M | 5.36M | 7.86M | 9.88M | 11.12M | 12.40M | 13.89M | 19.88M | 19.56M | 23.79M | 27.69M | 30.68M | 32.22M | 36.76M | 33.56M | 37.48M | 42.65M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -17.19M | -43.22M | -71.66M | -114.36M | -158.83M | -191.41M |
| Net Income | -17.12M | -42.81M | -67.64M | -100.16M | -133.81M | -167.79M |
| Diluted EPS | -23.17 | -1.14 | -1.26 | -1.57 | -1.45 | -1.63 |
| R&D Expense | 14.98M | 32.19M | 54.03M | 90.91M | 126.97M | 151.39M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 131.14M | 285.23M | 367.10M | 340.04M | 486.82M | 552.60M |
| Total Equity | -16.85M | -33.42M | 274.38M | 346.72M | 318.83M | 459.22M | 522.26M |
| Cash & Equivalents | - | 104.92M | 15.57M | 21.99M | 86.10M | 41.67M | 61.15M |
| Total Liabilities | - | 4.34M | 10.85M | 20.39M | 21.20M | 27.60M | 30.35M |
| Current Liabilities | - | 4.34M | 10.52M | 16.59M | 16.77M | 23.86M | 27.37M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -14.63M | -33.51M | -52.63M | -91.95M | -109.03M | -143.82M |
| Investing Cash Flow | -24.38M | -242.23M | -70.58M | 102.89M | -184.66M | -32.79M |
| Financing Cash Flow | 120.28M | 186.38M | 129.64M | 53.17M | 249.25M | 196.09M |
| Capital Expenditure | -203.00K | -668.00K | -5.55M | -5.75M | -1.31M | -256.00K |
| Free Cash Flow | -14.84M | -34.17M | -58.18M | -97.69M | -110.34M | -144.07M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 51.2% | -15.6% | -19.5% | -31.4% | -29.1% | -32.1% |
| ROCE % | -13.6% | -15.7% | -20.4% | -35.4% | -34.3% | -36.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Orbimed Advisors LLC. | 14.42% | 15.52M | $616.55M |
| 2 | RA Capital Management, L.P. | 9.69% | 10.43M | $414.32M |
| 3 | Paradigm Biocapital Advisors LP | 6.85% | 7.37M | $292.61M |
| 4 | Baker Bros. Advisors, LP | 6.11% | 6.58M | $261.26M |
| 5 | Blackrock Inc. | 6.02% | 6.47M | $257.17M |
| 6 | Janus Henderson Group PLC | 5.50% | 5.92M | $235.03M |
| 7 | Novo Holdings A/S | 4.97% | 5.35M | $212.56M |
| 8 | Driehaus Capital Management, LLC | 4.16% | 4.48M | $177.91M |
| 9 | Siren, L.L.C. | 4.12% | 4.43M | $176.01M |
| 10 | Perceptive Advisors Llc | 4.11% | 4.42M | $175.76M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EWTX
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE4zelNXc0dkREJNRXFBcUM2N3JmdlgxRzVtMWdrZ1I5bnZLdF92WklnV0taQ0l6NTh0RTk0ekt0eEJDQ2VhN2lWNEpWQ1VhU3NQ?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Biotech Edgewise banks $1.55B upfront, pivots fully to heart drugs - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNNXNnenF3VEd3TlJ3MEltcXMxRW90MTFKYU5RMG11TndRTnlQMm9SNU9lck4wQ3lEbFNuVU9vMmR3VGpjXzZVSll0ZGdCRU9BUXNfeTBxeGVjcHZYY0VxY3lqVXh4ekpuVGdDbTNXZ3Fyb05RRFBJVmFRalQyWjJLMmYyaks2TUcwaFJJWF…
Edgewise Therapeutics Stock Rides A 5-Day Winning Streak To A 23% Gain - Trefis
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxOZGV1ZWxvVWNaZE5sbmNFbC0wZmF5Q3VXX041Y1lSNFRyT25GZV9jTzNCUDNrWTdhNzFMRkJFVUZWd3MzaDl3X05HblpwZFlMQXlwZXhWZGpoVF9QUXlYd2RnTHhMdEs1RldNcVhwMHpxNUhFb0dlVnJQWURja2M3aUN2d0RXeDdXN25raU…
Edgewise Therapeutics (EWTX) Stock Looks Fully Priced After Phase 2 HCM Progress - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxQY2NBdnhhS0V3ZHdNdnZ4ekRZblNUZXFPVGtNRWpwaGI0NTItblBPMUxEMlAxREMzWkduQnplWEJoUDBvY3VMTEw1d2FZZW5SVGc4MDd6WG9xeG96bnZyY1hOWW1GWFcxamlKWUthVlhGeVh3ZVg0UTJIUjMzNnZxY3FvMGpPVGZIZFNMWG…
Positive Trial Results Propel Edgewise's (EWTX) Plans for Phase 3 Development - GuruFocus
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQenpLb0cteU5ENHpYb28xckdncGZhZFlhN25aWVdLMVQtd29ZSFo2ZGtIeTFPTk4tU0tHdkU3QU1rUV91LTFJRHJjckpEb1FlMEM5UHNQMURkZlF0T1FiU1EyVUV5aFo0NHNxbDBJaV9hWmY5UWdkWGVMaWxLRWl5RlRIUXpZcmowMlVKen…
Is Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNRW5ZcVlkaVVIelhJN2UzVUR5bzctZUVpeWdpSng5dzhxbHUyN0NTeUF1YkhSRVh1eTZkQjNVYzdPZzJFZlNnUzJtM0hoaWxOU1NHQWJLSEpsZ1lyTElhejBnUlk2NjN2TGcxWnRtMV9SRjktNWwyZjhsTEVLNHE0ajFSaFJ5YnplQlRadF…
EWTX — Frequently Asked Questions
What is the current share price of Edgewise Therapeutics, Inc. (EWTX)?
As of 2026-07-15 16:51 PDT, Edgewise Therapeutics, Inc. (EWTX) trades at $40.83 on NasdaqGS. Its 52-week range is $12.68 to $48.35.
What is the market capitalisation of EWTX?
Edgewise Therapeutics, Inc. (EWTX) has a market capitalisation of $4.39B on NasdaqGS.
What is the P/E ratio of EWTX?
EWTX trades at a trailing price-to-earnings (P/E) ratio of -24.60. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 8.66.
What is the return on equity (ROE) of EWTX?
EWTX has a return on equity (ROE) of -38.14%. Its return on capital employed (ROCE) is -36.44%.
Is EWTX a good stock to buy?
This page provides a data-driven analysis of Edgewise Therapeutics, Inc. (EWTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.